Q1 EPS Estimate for Corcept Therapeutics Lifted by Analyst

Corcept Therapeutics Incorporated (NASDAQ:CORTFree Report) – Equities research analysts at Zacks Research boosted their Q1 2026 earnings per share estimates for shares of Corcept Therapeutics in a research note issued on Monday, January 27th. Zacks Research analyst K. Das now anticipates that the biotechnology company will earn $0.46 per share for the quarter, up from their previous forecast of $0.45. The consensus estimate for Corcept Therapeutics’ current full-year earnings is $1.35 per share. Zacks Research also issued estimates for Corcept Therapeutics’ Q2 2026 earnings at $0.56 EPS, Q3 2026 earnings at $0.74 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.50 EPS.

Corcept Therapeutics (NASDAQ:CORTGet Free Report) last released its earnings results on Wednesday, October 30th. The biotechnology company reported $0.41 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.14. The firm had revenue of $182.55 million for the quarter, compared to analysts’ expectations of $171.97 million. Corcept Therapeutics had a return on equity of 24.54% and a net margin of 22.35%. The company’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.28 earnings per share.

Other research analysts have also recently issued reports about the stock. Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $78.00 to $130.00 and gave the stock a “buy” rating in a report on Thursday. Sandler O’Neill restated a “buy” rating on shares of Corcept Therapeutics in a report on Friday, October 18th. HC Wainwright reiterated a “buy” rating and set a $80.00 target price on shares of Corcept Therapeutics in a research note on Thursday, October 31st. Finally, StockNews.com lowered Corcept Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Monday, November 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $88.25.

View Our Latest Stock Analysis on Corcept Therapeutics

Corcept Therapeutics Stock Performance

Shares of Corcept Therapeutics stock opened at $69.90 on Wednesday. Corcept Therapeutics has a 1 year low of $20.84 and a 1 year high of $70.60. The firm’s 50-day moving average is $55.83 and its 200 day moving average is $46.67. The stock has a market cap of $7.32 billion, a price-to-earnings ratio of 55.48 and a beta of 0.56. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.70 and a quick ratio of 3.64.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CORT. Capital Performance Advisors LLP bought a new position in shares of Corcept Therapeutics during the 3rd quarter valued at approximately $25,000. Kathleen S. Wright Associates Inc. bought a new stake in Corcept Therapeutics during the 3rd quarter worth approximately $36,000. USA Financial Formulas purchased a new position in Corcept Therapeutics during the fourth quarter valued at approximately $54,000. Newbridge Financial Services Group Inc. bought a new position in shares of Corcept Therapeutics in the fourth quarter worth approximately $58,000. Finally, Principal Securities Inc. increased its stake in shares of Corcept Therapeutics by 63.6% in the fourth quarter. Principal Securities Inc. now owns 1,243 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 483 shares in the last quarter. Institutional investors own 93.61% of the company’s stock.

Insider Activity

In other Corcept Therapeutics news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $50.54, for a total value of $111,188.00. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Joseph Douglas Lyon sold 1,411 shares of the business’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $56.72, for a total transaction of $80,031.92. Following the sale, the insider now directly owns 8,494 shares of the company’s stock, valued at approximately $481,779.68. The trade was a 14.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 31,405 shares of company stock valued at $1,627,772 in the last ninety days. 20.50% of the stock is currently owned by company insiders.

About Corcept Therapeutics

(Get Free Report)

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.

Read More

Earnings History and Estimates for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.